Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Telomelysin + Radiation in Esophageal Cancer
NCT03213054Phase 1Unknown
- Sponsor
- Oncolys BioPharma Inc.
- Start
- Jul 2017
- Primary completion
- Mar 2019
- Modality
- Oncolytic Viruses
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of suratadenoturev in esophageal cancer, sponsored by Oncolys BioPharma Inc. Primary endpoints: Occurrence of Dose Limiting Toxicity at 18 weeks and Incidence rate of adverse event at 18 weeks. Status: unknown.
02
Drugs
suratadenoturev
03
Conditions
esophageal cancer
Beyond the preview
Go deeper on NCT03213054.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03213054.